Incidence and Prevalence of Psoriasis in Denmark
The incidence and temporal trends of psoriasis in Denmark between 2003 and 2012 were examined. There was a female predominance ranging between 50.0% (2007) and 55.4% (2009), and the mean age at time of diagnosis was 47.7–58.7 years. A total of 126,055 patients with psoriasis (prevalence 2.2%) were i...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Society for Publication of Acta Dermato-Venereologica
2017-05-01
|
Series: | Acta Dermato-Venereologica |
Subjects: | |
Online Access: |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2672
|
id |
doaj-a307267b759443be8533ffefdc32fc11 |
---|---|
record_format |
Article |
spelling |
doaj-a307267b759443be8533ffefdc32fc112020-11-25T00:11:58ZengSociety for Publication of Acta Dermato-VenereologicaActa Dermato-Venereologica0001-55551651-20572017-05-0197780881210.2340/00015555-26724952Incidence and Prevalence of Psoriasis in DenmarkAlexander Egeberg0Lone SkovGunnar H. GislasonJacob P. ThyssenLotus Mallbris Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark. alexander.egeberg@gmail.com. The incidence and temporal trends of psoriasis in Denmark between 2003 and 2012 were examined. There was a female predominance ranging between 50.0% (2007) and 55.4% (2009), and the mean age at time of diagnosis was 47.7–58.7 years. A total of 126,055 patients with psoriasis (prevalence 2.2%) were identified. Incidence rates of psoriasis (per 100,000 person years) ranged from 107.5 in 2005 to a peak incidence of 199.5 in 2010. Incidence rates were higher for women, and patients aged 60–69 years, respectively. Use of systemic non-biologic agents, i.e. methotrexate, cyclosporine, retinoids, or psoralen plus ultraviolet A (PUVA) increased over the study course, and were used in 15.0% of all patients. Biologic agents (efalizumab, etanercept, infliximab, adalimumab, or ustekinumab) were utilized in 2.7% of patients. On a national level, incidence of psoriasis fluctuated during the 10-year study course. The relationship between psoriasis incidence and age appeared to be relatively linear, and disease prevalence was comparable to that in other European countries. https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2672 psoriasisincidenceprevalenceepidemiology |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alexander Egeberg Lone Skov Gunnar H. Gislason Jacob P. Thyssen Lotus Mallbris |
spellingShingle |
Alexander Egeberg Lone Skov Gunnar H. Gislason Jacob P. Thyssen Lotus Mallbris Incidence and Prevalence of Psoriasis in Denmark Acta Dermato-Venereologica psoriasis incidence prevalence epidemiology |
author_facet |
Alexander Egeberg Lone Skov Gunnar H. Gislason Jacob P. Thyssen Lotus Mallbris |
author_sort |
Alexander Egeberg |
title |
Incidence and Prevalence of Psoriasis in Denmark |
title_short |
Incidence and Prevalence of Psoriasis in Denmark |
title_full |
Incidence and Prevalence of Psoriasis in Denmark |
title_fullStr |
Incidence and Prevalence of Psoriasis in Denmark |
title_full_unstemmed |
Incidence and Prevalence of Psoriasis in Denmark |
title_sort |
incidence and prevalence of psoriasis in denmark |
publisher |
Society for Publication of Acta Dermato-Venereologica |
series |
Acta Dermato-Venereologica |
issn |
0001-5555 1651-2057 |
publishDate |
2017-05-01 |
description |
The incidence and temporal trends of psoriasis in Denmark between 2003 and 2012 were examined. There was a female predominance ranging between 50.0% (2007) and 55.4% (2009), and the mean age at time of diagnosis was 47.7–58.7 years. A total of 126,055 patients with psoriasis (prevalence 2.2%) were identified. Incidence rates of psoriasis (per 100,000 person years) ranged from 107.5 in 2005 to a peak incidence of 199.5 in 2010. Incidence rates were higher for women, and patients aged 60–69 years, respectively. Use of systemic non-biologic agents, i.e. methotrexate, cyclosporine, retinoids, or psoralen plus ultraviolet A (PUVA) increased over the study course, and were used in 15.0% of all patients. Biologic agents (efalizumab, etanercept, infliximab, adalimumab, or ustekinumab) were utilized in 2.7% of patients. On a national level, incidence of psoriasis fluctuated during the 10-year study course. The relationship between psoriasis incidence and age appeared to be relatively linear, and disease prevalence was comparable to that in other European countries. |
topic |
psoriasis incidence prevalence epidemiology |
url |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2672
|
work_keys_str_mv |
AT alexanderegeberg incidenceandprevalenceofpsoriasisindenmark AT loneskov incidenceandprevalenceofpsoriasisindenmark AT gunnarhgislason incidenceandprevalenceofpsoriasisindenmark AT jacobpthyssen incidenceandprevalenceofpsoriasisindenmark AT lotusmallbris incidenceandprevalenceofpsoriasisindenmark |
_version_ |
1725402009703546880 |